To clarify, the objective of the AREDS 2 study was to determine if the addition of Zeaxanthin, Lutein, and Omega 3’s to the original AREDS formula would further reduce the progression to advanced AMD vs. the original AREDS formulation. Numerous clinical studies suggest these nutrients protect vision.
Dr. Emily Chew, Deputy Clinical Director at the National Eye Institute and Deputy Director of the NEI Division of Epidemiology and Clinical Applications stated, “The addition of lutein and zeaxanthin to the AREDS formulation in the analysis showed a 10% decrease in the risk of progression to advanced AMD.”
AREDS 2 study results – Reduction in Progression to Advanced AMD
AREDS formula and lutein + zeaxanthin vs. AREDS with beta-carotene:
AREDS formula and lutein + zeaxanthin vs. AREDS formula with no lutein + zeaxanthin:
Results published in JAMA Ophthalmology evaluated the effects of lutein + zeaxanthin on progression to cataract surgery, development of any cataract, or development of severe cataract. The results showed that in subjects in the lowest quintile of dietary lutein and zeaxanthin:
Dr. Chew also said, “When we looked at just those participants in the study who took an AREDS formulation with lutein and zeaxanthin but no beta-carotene, their risk of developing advanced AMD over the five years of the study was reduced by about 18 percent, compared with participants who took an AREDS formulation with beta-carotene but no lutein or zeaxanthin. Further analysis showed that participants with low dietary intake of lutein and zeaxanthin at the start of the study, but who took an AREDS formulation with lutein and zeaxanthin during the study, were about 25 percent less likely to develop advanced AMD compared with participants with similar dietary intake who did not take lutein and zeaxanthin.”
While Omega-3s did not show benefits in reducing the progression to advanced AMD, numerous studies have confirmed that DHA is a major component of the retina, and is beneficial to eye health and other organ systems.
About AREDS 2
As previously mentioned, the AREDS 2 study was conducted to determine if the addition of Zeaxanthin, Lutein, and Omega 3’s would further reduce the progression to advanced AMD vs. the original AREDS supplement formulation.
The AREDS 2 protocol was designed to study the possibility of slowing disease progression to advanced AMD. According to the NEI, the types of patients in the AREDS 2 study had, “…bilateral large drusen (≥ _125 microns) or large drusen in one eye and advanced AMD in the fellow eye. Additionally, a study eye without advanced AMD may have definite geographic atrophy not involving the center of the macula without evidence of drusen.”
The original AREDS study results were released in 2001, and revealed that high-dose antioxidant vitamins and minerals including Vitamins C and E, Beta-Carotene, Zinc, and Copper reduced the risk of progression to advanced AMD by 25 percent, and the risk of moderate vision loss by 19 percent.
ZeaVision, EyePromise, and AREDS 2
At ZeaVision, we pioneered the use of Zeaxanthin for eye health, introducing the first commercially available zeaxanthin-based supplement the same year the original AREDS results were published. Since that time, ZeaVision has sponsored ongoing research and developed the highest quality ocular nutraceuticals to fight vision loss and preserve healthy vision. We are delighted that the AREDS 2 Study confirms what numerous clinical studies have reported over the years – that Zeaxanthin and Lutein are important to macular health.
How is the AREDS 2 Formula Different Than the Original AREDS Formula:
The AREDS 2 recommendation differs from the original AREDS by:
Some lesser-known facts about the AREDS 2 protocol:
Study participants were allowed to take a multi-vitamin and asked to standardize to the same formulation. It is well documented that multi-vitamins contain many ingredients that are beneficial to ocular health as well as overall health. Dr. Emily Chew confirmed that 90% of AREDS 2 participants took a Centrum multi-vitamin daily.
What About EyePromise Restore?
Since 2010, EyePromise Restore has contained AREDS 2 ingredients along with additional ingredients such as Vitamin D, Alpha Lipoic Acid, and Mixed Tocopherols. It is estimated that approximately 70% of the US population is deficient in Vitamin D and a recent clinical study suggests it may lower AMD risk. Finally, scientific research supports the beneficial properties of Alpha Lipoic Acid and Mixed Tocopherols.
It is important to underscore that EyePromise Restore is an evidence based eye vitamin designed to maintain macular health. EyePromise Restore and all zeaxanthin-based EyePromise brands are guaranteed to increase MPOD, backed by a money-back guarantee. Please visit explore.eyepromise.com/mpodguarantee for more information on the EyePromise Guaranteed to Increase MPOD! offer.
EyePromise Restore remains the preferred doctor recommended eye vitamin designed to quickly increase MPOD (Macular Pigment Optical Density) in those wanting to protect and enhance their vision in a convenient daily dose of only 1 or 2 small softgels.
Does the AREDS 2 Study Affect MPOD?
MPOD (Macular Pigment Optical Density) continues to be recognized as an important biomarker for macular health, particularly patients with risk factors for AMD. A large body of scientific evidence demonstrates that low MPOD is a key risk factor for AMD. We encourage all of our customers to have their MPOD measured, and if you would like to locate a doctor in your area with a QuantifEye® MPOD measurement instrument, please call Customer Support at (866) 833-2800, or via email at firstname.lastname@example.org.
Please join us in celebrating the exciting news around the AREDS 2 study results and the opportunity to fight vision loss and preserve healthy vision!
Article on Baby Boomers and AREDS 2